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E-mail address: mboyd@liv.ac.uk (M.T. Boyd).Recent studies connect MDM2 with increased cell motility, invasion and/or metastasis proposing an
MDM2-mediated ubiquitylation-dependent mechanism. Interestingly, in renal cell carcinoma (RCC)
p53/MDM2 co-expression is associated with reduced survival which is independently linked with
metastasis. We therefore investigated whether expression of p53 and/or MDM2 promotes aggressive
cell phenotypes. Our data demonstrate that MDM2 promotes increased motility and invasiveness in
RCC cells (N.B. similar results are obtained in non-RCC cells). This study shows for the ﬁrst time both
that endogenous MDM2 signiﬁcantly contributes to cell motility and that this does not depend upon
the MDM2 RING-ﬁnger, i.e. is independent of ubiquitylation (and NEDDylation). Our data suggest
that protein–protein interactions provide a likely mechanistic basis for MDM2-promoted motility
which may constitute future therapeutic targets.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
In addition to its well-documented and proven role as critical
negative regulator of p53 (reviewed in [1]), MDM2 has been shown
to display p53-independent oncogenic activities (reviewed in [2]).
For example, studies in NIH3T3 cells have shown that naturally
occurring splice variants of MDM2 that lack the ability to bind to
p53 retain transforming activity [3]. Additional evidence from
in vivo studies of mice expressing an MDM2 transgene from a b-
lactoglobulin promoter have demonstrated abnormal mammary
development and cell cycle deregulation in both p53 wild-type
and null backgrounds [4]. Further evidence has been provided by
studies of mice that over-expressed MDM2 from the MDM2 pro-
moter which developed a different spectrum of tumours c.f. p53
null mice [5], regardless of their p53 status. MDM2 expression
has also been shown to abrogate the growth inhibitory activities
of Transforming Growth Factor-Beta1 (TGFb1) in a p53-indepen-
dent manner in cells in culture [6]. More recently, we have shown
that MDM2 mono-ubiquitylates DHFR, altering cellular sensitivity
to methotrexate and inhibiting DHFR activity in tumour cells in achemical Societies. Published by E
ery and Oncology, School of
uilding, Daulby St., Liverpoolp53-independent manner [7], thus implicating MDM2 in the regu-
lation/de-regulation of one carbon metabolism with potentially
wide-ranging consequences.
Recent work has suggested links between MDM2 and cell motil-
ity, invasion and metastatic potential although the mechanisms
leading to this remain unclear (discussed below) [8,9]. Our study
was initiated to investigate renal cancer cells because unlike the
situation pertaining in most other cancers, we have recently found
that in renal cell carcinoma, the most common form of renal can-
cer, up-regulated p53 is usually wild-type and is linked with up-
regulation of MDM2 (see [10] for review of the literature and also
Noon et al., submitted). Since co-expression of p53 and MDM2 is
linked with poor outcome, we speculated that this might promote
more aggressive behaviour/s in renal cells such as increased motil-
ity and invasiveness leading to increased metastasis. We therefore
set out to investigate whether p53 and MDM2 expression in renal
cancer cells altered their motility and invasiveness and in the
course of these studies have also found that these properties are
not limited to renal cells, but extend to other cell types.
In a recent study, it was proposed that MDM2 promotes motil-
ity through the ability of its E3 ubiquitin ligase activity to target
SLUG (SNAI2) for degradation [8]. This study showed that in cells
expressing high levels of MDM2, SLUG levels were reduced and
motility increased. In another study it was found that MDM2 levels
in breast cancer cells inversely correlated with E-cadherin levelslsevier B.V. All rights reserved.
4696 R. Polan´ski et al. / FEBS Letters 584 (2010) 4695–4702and that high MDM2/low E-cadherin was associated with axillary
lymph node metastasis [9]. Whilst these authors did show that ec-
topic expression of MDM2 increased motility in MCF-7 cells, nei-
ther they, nor the authors of the other study directly assessed
the contribution of endogenous MDM2 to motility or invasion,
e.g. through RNAi studies (it was addressed only through correla-
tion studies). Also, whilst several correlative experiments were de-
scribed, no data were presented in either study that tested whether
an intact MDM2 RING-ﬁnger, a prerequisite for its function as an
ubiquitin ligase, is required for MDM2-promoted motility or inva-
sion. We therefore included analysis of these properties in the
present study and show for the ﬁrst time that endogenous
MDM2 contributes to cell motility and that mutant MDM2 which
lacks a functional RING ﬁnger, retains the ability to promote in-
creased cell motility. It may be noteworthy that in parallel studies,
we found no evidence for any detectable change in SLUG levels in
these more motile cells, nor did we ﬁnd changes in E-cadherin lev-
els in highly motile cells expressing wt or RING ﬁnger mutant
MDM2 in our analyses.
Thus a key conclusion from our studies is that MDM2 possesses
motility promoting activity that does not require its function as an
ubiquitin ligase. This not only suggests that previously unidentiﬁed
mechanism/s determine the capacity of MDM2 to promote motility0
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Fig. 1. p53 and/or MDM2 promote cell motility in RCC cells. Histograms display resul
transfected with the indicated siRNAs. Cells were transfected with siRNA and 24 h later w
prior to counting. Results are mean ± S.E.M. Experiments shown are typical from a single
and analysed separately (n = 3). Statistical analysis performed using Student’s t-test. Pan
probed with the indicated antibodies.and invasion, but also is most compatible with a protein–protein
interaction-based mechanism. This may be of particular impor-
tance in renal cancers where this mechanism likely contributes
to the observed link between p53/MDM2 co-expression and re-
duced patient survival and thus we predict that a novel protein–
protein interactive site is present that may be targeted for thera-
peutic intervention.2. Materials and methods
2.1. Antibodies
The mouse monoclonal antibody for b-actin (C-2) used as a pro-
tein loading control in SDS–PAGE, was purchased from Santa Cruz
Biotechnology. The mouse monoclonal antibodies used in western
analysis for MDM2 (Ab-1/clone IF2) and p53 (Ab-6/clone DO-1)
were purchased from EMD Biosciences. Secondary antibody anti-
mouse was from GE Healthcare.
2.2. Plasmids and siRNAs
The expression vectors for human p53 (pCEP4-p53), MDM2
(pCMVneobam-MDM2) and RING-ﬁnger mutant of MDM2 (pCMV-M2
M2
MDM2
β-actin
p53
MDM2
β-actin
p53
siRNA
siRNA
ts of motility experiments with the indicated cell lines (A = A498 and B = Caki-2),
ere seeded into Boyden chambers. Eighteen hours later the membranes were stained
experiment and for each condition three independent transfections were performed
els to the right of histograms display western blot analyses of samples from A and B
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bam and pCEP4 (obtained from Invitrogen) have been described
previously [11]. A dominant negative mutant of p53 (R175H)
pCB6+p53 175His, kindly provided by Prof. Karen Vousden, was
sub-cloned to create pCEP4-p53(R175H). The GFP expression vec-
tor pSUPER-EGFP was obtained from Oligoengine. siRNAs for p53
(50 GGACAUACCAGCUUAGAUU 30), MDM2 (50 GCCACAAAUCU-
GAUAGUAU 30), and a scrambled control (50 GGACGCAUCCUU-
CUUAAUU 30) have been described previously [12–14] [12]and
were synthesized by Dharmacon.
2.3. Cell lines and transfection
The cell lines A498 (primary RCC, p53 wild-type), Caki-2 (pri-
mary clear cell RCC, p53 wild-type), 117 (p53 wild-type-kindly
provided by Prof. W.M. Linehan), H1299 (non-small cell lung
carcinoma, p53 null) and Clone 9 (a H1299 derivative which sta-
bly over-expresses MDM2) have been described previously
[7,14]. A498, and 117 cells (and clonal derivatives) were main-
tained in Eagle’s MEM supplemented with 2 mM L-glutamine,
1.5 g/l sodium bicarbonate, 0.1 mM non-essential amino acids,
1 mM sodium pyruvate and 10% FBS. H1299 and Clone-9 cells
were maintained in DMEM supplemented with 2 mM L-gluta-
mine and 10% FBS. Caki-2 cells were maintained in McCoy’s 5A
supplemented with 1.5 mM L-glutamine, 2.2 g/l sodium bicarbon-
ate and 10% FBS. Cells were transiently transfected using 3 ll
GeneJuice reagent (Novagen) per microgram of DNA, and empty
vector was used to ensure equal DNA content in transfections.
siRNA was delivered to cells by transfection with Lipofect-
amine 2000 (Invitrogen) according to the manufacturer’s
instructions.P=0.005
P=0.00000001
A
B
H1299
Fig. 2. MDM2 promotes cell motility in non-RCC cells. (A) H1299s and Clone 9 cells –
assayed for motility essentially as described in Fig. 1. (B) H1299 cells were transfected w
as described in Fig. 1. Results are mean ± S.E.M. Experiments shown are typical from
performed and analysed separately (n = 3). Statistical analysis performed using Student’
indicated cells probed with the indicated antibodies from the same samples assayed for2.4. Western blotting
Cells were harvested by trypsinisation after the indicated times
and pelleted by centrifugation. Cell pellets were lysed in SLIP buffer
(50 mM HEPES pH 7.5, 10% glycerol, 0.1% Triton-X100, 150 mM
NaCl) in the presence of the following protease inhibitors: aproti-
nin (2 lg/ml), leupeptin (0.5 lg/ml), pepstatin A (1 lg/ml), soy-
bean trypsin inhibitor (100 lg/ml) and phenylmethylsulfonyl
ﬂuoride (PMSF) (1 mM). After 10 min incubation on ice, lysates
were centrifuged at 20,000g and protein concentrations in the
supernatant were determined using Bradford reagent (BioRad).
Typically, 50 lg samples of total protein in 1  protein sample buf-
fer (50 mM Tris–HCl (pH 6.8), 2% SDS, 10% glycerol, 0.25% b-
mercaptoethanol, bromophenol blue (1 mg/ml)) were separated
by SDS–PAGE and transferred to Hybond ECL nitrocellulose mem-
brane (GE Healthcare). Membranes were blocked in PBS-Tween-20
(0.1% v/v) containing non-fat dry milk (BioRad) (5% w/v) for 1 h at
room temperature before incubation with primary antibodies
(each at 3 lg/ml, except anti-p53 at 1 lg/ml). Membranes were
washed three times for 15 min in PBS-Tween-20 before addition
of HRP-conjugated anti-mouse (1:2500) secondary antibody (GE
Healthcare) for 1 h at room temperature. Membranes were washed
as before and signal was detected by Western Lightning Chemilu-
minescence Reagent (Perkin–Elmer) either on ﬁlm or using a KO-
DAK IS4000MM system.
2.5. Drug selection of transfected cells in hygromycin B and G418
Sub-clones of 117 cells transfected with plasmids conferring
resistance to G418 (pCMVneobam [pCMV] and pCMVneobam-
MDM2 [pMDM2]) and hygromycin B (pCEP4 and pCEP4-p535
MDM2
β-actin
MDM2
β-actin
an isogenic clonal derivative of these that stably expresses increased MDM2, were
ith either an siRNA for MDM2 or a scrambled control and their motility was assayed
a single experiment and for each condition three independent transfections were
s t-test. Panels on the right display western blots of the proteins extracts from the
motility.
4698 R. Polan´ski et al. / FEBS Letters 584 (2010) 4695–4702(R175H) [p53(R175H)]) were generated according to the scheme
shown in Fig. 3C. Brieﬂy, cells were transfected with the indicated
plasmid and 24 h later were transferred into media containing
either 800 lg/ml G418 (Calbiochem) and/or 250 lg/ml hygromy-
cin B (Roche) as required. Media with fresh antibiotic was replaced
every 2–3 days and 10–21 days later colonies were picked and ex-
panded prior to analysis by western blotting.
2.6. Motility and invasion assays
Typically 1  104–5  104 cells were seeded into each Boyden
chamber (VWR) that was inserted into a 24-well plate containing
approximately 300 ll of cell culture media, essentially as described
[15]. After 18 h, the inside of each chamber was scraped rigorously
with cotton buds to ensure there were no cells adhering on the in-
ner side of the chamber membrane. Cells were then ﬁxed and
stained with REASTAIN Quick-Diff Kit (Reagenta, Gamidon) accord-
ing to the manufacturer’s protocol. Brieﬂy, the cells were ﬁxed inC
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Fig. 3. Generation of cells that stably express higher levels of MDM2. (A) 117 (RCC) ce
control as indicated. (B) Colonies obtained from (A) were picked, expanded and protein l
indicated. Note that the MDM2-transfected H1299 lysate was under-loaded to prevent t
readily achieved, stable expression was not detectable. (C) A scheme to generate 117 ce
text). Details of the cell clones produced are listed in Supplementary data Fig. 2 and a sREASTAIN Quick-Diff Fix for 10 min and thereafter stained with
REASTAIN Quick-Diff Red followed by REASTAIN Quick-Diff Blue
for 2 min each. The chambers were then rinsed in H2O to remove
any excess stain and allowed to dry for 30 min. Dried membranes
were excised from the chamber and mounted onto microscopic
slides with DPX (Sigma) mountant. To determine the number of
cells that had passed through the chamber membrane, the mem-
brane was divided into four or more grids. Digital images of each
grid were counted manually. Three chambers were counted for
each sample and the average number of cells that passed through
to the outer chamber membrane has been represented in graphical
format. For invasion assays, BD-Matrigel™ invasion chambers
(Becton Dickinson) were used.
3. Results
In a recent study (Noon et al., submitted) we conﬁrmed previ-
ous studies which had found that p53 and MDM2 are frequently117 + MDM2
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Fig. 4. Up-regulation of p53 and MDM2 promotes increased motility and invasion
in RCC cells. (A) Cell clones derived from the 117 cell line following the
experimental scheme described in Fig. 3C and selected from the clones listed/
summarised in Supplementary data Fig. 2/Supplementary data Table 1, respec-
tively, were analysed by western blotting for the indicated proteins. (B) The same
cell lines were seeded into Boyden chambers for 18 h and were then stained and
counted. (C) As for (B) but cells were seeded into Matrigel™ coated chambers.
Results are mean ± S.E.M. Experiments shown are typical from a single experiment
and for each condition three independent transfections were performed and
analysed separately (n = 3). Statistical analysis performed using Student’s t-test.
R. Polan´ski et al. / FEBS Letters 584 (2010) 4695–4702 4699co-expressed in RCC [16,17]. We also conﬁrmed that co-expres-
sion of p53 and MDM2 is linked with reduced disease-speciﬁc
survival as Haitel et al. had previously shown [16]. In addition,
we showed for the ﬁrst time that the p53 co-expressed with
MDM2 was frequently wild-type (in 86% of co-expressing cases,
Polanski et al., submitted), which suggests that MDM2 up-regula-
tion may be a consequence of p53 up-regulation as we have pre-
viously proposed [10,14]. Our working hypothesis is that co-
expression of wild-type p53 and MDM2 promotes disease pro-
gression in RCC and thus we examined phenotypes in RCC cells
that may contribute to this process. RCC patients with metastatic
disease have an extremely short life expectancy and most patients
who die from the disease do so as a consequence of metastatic
spread [18]. Since motility and invasiveness are key cellular deter-
minants of metastatic potential we have therefore examined the
former processes in vitro. To determine whether p53 and/or
MDM2 contribute to motility in renal cancer cells we transfected
siRNAs for p53, MDM2 and for p53+MDM2 into two wt p53 renal
carcinoma lines A498 and Caki-2 that co-express high levels of
wild-type p53 and MDM2 (see Supplementary data Fig. 1) and
which thus mimic the co-expression that occurs in a sub-set of
poor prognosis RCC patients.
As Fig. 1 shows, reducing p53 and/or MDM2 expression with
siRNA leads to signiﬁcant reductions in motility in these cells. siR-
NA for MDM2 appears to be more effective at inhibiting motility
than p53 siRNA transfection, but since targeting both p53 and
MDM2 rescues this difference in A498 cells, this may be due to
other effects of p53 induction in cells transfected only with
MDM2 siRNA as we have previously described [14] (note that we
have not observed evidence of reduced viability during these
experiments, though these cells do display increased evidence of
senescence). From these data we conclude that both p53 and
MDM2 contribute to motility in RCC cells.
Whilst the focus of our study is on renal cancer cells, we wanted
to determine both whether this effect is more general and if so, to
take advantage of p53 null cancer cells from other tissues to exam-
ine the contribution of MDM2 in a p53-free environment. In a pre-
vious study we used a clone of H1299 cells (Clone 9) that stably
express high levels of MDM2 from an integrated plasmid [7]. We
tested the motility of these cells and found that Clone 9 cells
expressing higher levels of MDM2 displayed increased motility as
Fig. 2A shows. To address the question of whether endogenous
MDM2 promotes motility and also to address concerns arising
from the clonal selection process used to produce Clone 9 cells,
we transfected MDM2 siRNA into H1299 cells which express low
levels of MDM2 (as illustrated in Fig. 3B where on longer exposure
the level of MDM2 in H1299 is comparable to the low level ex-
pressed in 117 cells, not shown). The result of this experiment is
demonstrated in Fig. 2B. Remarkably, this experiment represents
the ﬁrst direct examination of endogenous MDM2 modulation
and motility in cells. We conclude that MDM2 possesses cell motil-
ity promoting activity that is p53-independent.
A substantial subset of RCC patients appear to progress from a
p53 low/MDM2 low phenotype to a more aggressive p53 high/
MDM2 high phenotype. To study this we were required to generate
RCC cells in vitro that would stably express higher levels of p53
and/or MDM2 (Supplementary data Fig. 1 shows the levels of
p53 andMDM2 expression in a panel of renal cancer cell lines com-
pared to U2OS cells which express comparable levels of MDM2 to
H1299 cells). We selected the RCC cell line 117 which harbour low
levels of both p53 (wild-type) and MDM2 for subsequent experi-
ments. As Fig. 3A and B shows, transfecting an MDM2 expression
plasmid into cells results in transient, but not stable expression
of higher levels of MDM2. This phenomenon, namely that MDM2
an oncogene activated through up-regulation cannot readily be
stably over-expressed in tumour cells, has been observed previ-ously [19]. At the time that we performed this experiment it was
not yet clear that the p53 co-expressed with MDM2 in RCC cells
was wild-type. Therefore we performed an experiment to test
whether expression of a wt or dominant negative mutant p53
could promote cells to tolerate high levels of MDM2. Not surpris-
ingly we did not obtain any stable clones following wt p53 trans-
fection, whereas numerous clones were obtained from cells
transfected with the empty vector or vector expressing dominant
negative p53 (R175H). We then took clones of cells that had been
transfected with either the empty vector or with a dominant neg-
ative p53 (R175H) through a second round of transfection as
shown in the scheme in Fig. 3C. The results of this cloning exercise
are summarised in Supplementary data Fig. 2 and Table 1. Essen-
tially these data show two things. RCC cells can spontaneously ac-
quire increased p53 and MDM2 expression (even in cells that have
received only empty vectors) and the in vitro results mimic the
in vivo results; MDM2 up-regulation was again signiﬁcantly asso-
ciated with high p53 expression (P < 0.01).
A key prediction of our studies is that up-regulation of p53 and
MDM2 promotes events leading to reduced disease-speciﬁc sur-
4700 R. Polan´ski et al. / FEBS Letters 584 (2010) 4695–4702vival with metastatic potential being a likely determinant of this
[18]. To investigate this we testedwhether isogenic RCC cells differ-
ing in their p53 and MDM2 expression levels would exhibit altered
motility. Fig. 4A and B shows that clones that express higher levels
of p53 and MDM2 also display increased motility. In addition to
motility, metastatic cells must acquire the ability to invade the
extracellular environment. We therefore investigated the ability
of the same clones shown in Fig. 4B to invade through Matrigel™.
As Fig. 4C demonstrates, cells expressing up-regulated p53 and
MDM2 were not only more motile (Fig. 4B), but were also more
invasive.We noted however, that cells expressing intermediate lev-
els of MDM2 (clones 1.16, 1.17 and 1.20), in the absence of up-reg-
ulated p53 (note 117 p53 level for comparison in Fig. 4A), were
neither more motile, nor more invasive. These differences in motil-
ity and invasiveness are not due to differences in the in vitro growth
rates of these cell clones as Supplementary data Fig. 3 shows. To
determine whether the increased motility shown in Fig. 4B was
due to p53 and/or MDM2 we used siRNA to modulate the expres-
sion of these genes in two highly motile clones 1.27 and 1.11. As
Fig. 5 demonstrates for the highly motile clones 1.27 and 1.11,
the motility of these cells is signiﬁcantly reduced only when
MDM2 siRNA is transfected. Note that these effects ofMDM2 reduc-
tion by siRNA transfection are not due to any impact upon cell pro-
liferation as Supplementary data Fig. 5 illustrates. Note also, thatB
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Fig. 5. MDM2 signiﬁcantly promotes increased motility in RCC cells that spontaneousl
experiments with the indicated cell lines (A = 1.27 and B = 1.11), transfected with the in
Boyden chambers. Eighteen hours later the membranes were stained prior to counting. Re
for each condition three independent transfections were performed and analysed separat
the histograms display western blot analyses of samples from A and B probed with thewhen p53 siRNA is used, MDM2 steady state levels of expression
are reduced. Thus in RCC cells not only is MDM2 up-regulated in
a p53-dependent manner as we showed elsewhere (Polanski et
al., submitted), but up-regulation of both p53 and MDM2, signiﬁ-
cantly associated with reduced disease-speciﬁc survival in vivo,
also promotes increased cellular motility and invasiveness in vitro.
Whilst the results presented may suggest that both p53 and
MDM2 play a role in regulating cell motility and invasiveness,
the evidence from p53 null cells (Fig. 2) and the data presented
in Fig. 5 suggest that MDM2 may be the primary determinant of
this process, with p53 performing an indirect function through
its ability to promote MDM2 expression. This conclusion is further
supported by analysis of one of the 117 clones that expresses mu-
tant p53 (R175H) and exogenous MDM2 (from integrated pCMV-
neobam-MDM2) and thus in these cells MDM2 expression is
p53-independent. When these cells are transfected with siRNA
for p53, p53 levels are reduced, but this has no impact on either
motility or on MDM2 levels. In contrast, when siRNA for MDM2
is transfected into these cells (with or without concomitant trans-
fection of p53 siRNA), then the cells display signiﬁcantly reduced
motility (illustrated in Supplementary data Fig. 4). Thus it appears
that MDM2 is a key determinant of motility in these RCC cells and
that any role for p53 in this process may depend upon its ability to
regulate MDM2 levels.DM2
M2
MDM2
β-actin
p53
MDM2
β-actin
p53
siRNA
siRNA
y acquire increased p53/MDM2 expression. Histograms display results of motility
dicated siRNAs. Cells were transfected with siRNA and 24 h later were seeded into
sults are mean ± S.E.M. Experiments shown are typical from a single experiment and
ely (n = 3). Statistical analysis performed using Student’s t-test. Panels to the right of
indicated antibodies.
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motility, invasion and/or metastasis. One concluded that MDM2
regulated the levels of E-cadherin expression, and that this deter-
mined motility and invasiveness [9], whilst the other concluded
that MDM2 promoted degradation of SLUG with the resulting in-
crease in E-cadherin expression promoting increased invasiveness
[8]. Neither study examined the effect of endogenous MDM2 sup-
pression with siRNA on motility/invasion or metastasis. Moreover,
since both studies proposed mechanisms that depend upon the
ubiquitin ligase activity of MDM2, it seemed surprising that nei-
ther tested whether a mutant of MDM2 that cannot carry out ubiq-
uitylation could promote motility.
To examine this we generated a panel of independent H1299
clones that express wild-type MDM2, a RING ﬁnger mutant of
MDM2 (C464A) or harbour the empty vector alone and have per-0
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was assessed as in (A). Note that for all experiments 15,000 cells were seeded/chamber.
probed with the indicated antibodies. For each motility assay three individual cultures w
counted. Statistical analyses by Student’s t-test (n = 3). Results are mean ± S.E.M. from
occasions.formed motility assays on these as Fig. 6A illustrates. Clones that
express either wild-type MDM2 or an ubiquitin ligase-dead mu-
tant (C464A) all exhibit signiﬁcantly increased cell motility. Since
multiple clones displayed comparable motility phenotypes, it is
unlikely that these effects are due to clonal selection. However,
to further rule out this possibility we also transiently transfected
H1299 cells with expression vectors for MDM2 and the same
RING-ﬁnger mutant of MDM2 (C464A) and examined the motility
of these cells. As Fig. 6B shows, cells that express either wt MDM2
or a RING-ﬁnger mutant also display signiﬁcantly increased
motility.
These results show that MDM2 increases motility, in a p53-
independent manner, through a mechanism that does not depend
upon the ubiquitin ligase activity of MDM2 [20]. We conclude that
the ability of MDM2 to promote increased motility likely dependsMDM2
β-actin
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P=0.0002
MDM2
β-actin
nt manner. (A) H1299 cells and stable clonal derivatives expressing either wild-type
amber as described in the methods. The panel below shows western blot analysis of
99 cells were transfected with the indicated expression plasmids and their motility
The panel on the right shows a western blot of protein lysates from the cells in (B)
ere analysed and for transfections three independent cultures were transfected and
a single typical experiment. Note that the H1299s were assayed on two separate
4702 R. Polan´ski et al. / FEBS Letters 584 (2010) 4695–4702upon protein–protein interactions which may have important
implications for drug targeting, particularly for RCC as discussed
below.4. Discussion
The initial focus of this study derived from an interest in the
role of p53/MDM2 expression in determining phenotypes linked
with poor outcome in RCC such as motility and invasiveness
([10] and Noon et al., submitted). However, the ensuing studies
have also, for the ﬁrst time, investigated two key questions arising
from earlier studies that indicated an association between MDM2
ubiquitin ligase activity and motility/invasion/metastasis [8,9]: (i)
does endogenous MDM2 promote cell motility and (ii) is the ubiq-
uitin-ligase activity of MDM2 required for this? Neither of the cited
studies examined the ability of endogenous MDM2 to promote
motility as we have here using RNAi to down-regulate endogenous
MDM2 (Figs. 1, 2 and 5). Furthermore, whilst these studies pro-
posed a role for MDM2-mediated ubiquitylation in promoting
motility/invasion and/or metastasis, neither tested an enzymati-
cally inactive mutant as we have in Fig. 6. Our data clearly demon-
strate that MDM2 can promote increased motility and invasiveness
in cells and that this does not depend upon an intact RING-ﬁnger
domain of MDM2. The RING-ﬁnger mutant that we have used,
C464A has been extensively used and is well-documented to lack
E3-ubiquitin ligase [20,21] activity. Also, an intact RING domain
is required for NEDDylation activities [22]. Thus the ability of
MDM2 to promote motility is independent of both MDM2-medi-
ated ubiquitylation and NEDDylation. Recent studies in mice have
proven that the RING domain of MDM2 is essential for MDM2-
mediated regulation of p53 [23]. Nevertheless, there are a number
of MDM2–protein interactions that may play important functional
roles that either do not, or at least appear not to depend upon the
enzyme activities (ubiquitylation and/or NEDDylation) encoded by
the RING domain (reviewed in [1]). MDM2 interacts with a consid-
erable number of proteins involved in a wide range of processes
and these protein–protein interfaces are potentially amenable to
drug targeting. To date, the best examples are drugs aimed at res-
cuing p53 from the negative regulation of MDM2 such as Nutlin-3
[24] and the MI-series of compounds [25]. It may be of interest in
this regard that in initial experiments using Nutlin-3 we have ob-
served an impact of Nutlin-3 on MDM2-mediated motility, and
moreover that cells expressing higher levels of MDM2 appear to
be resistant to this effect (see Supplementary data Fig. 6). Both
Nutlin-3 and the MI compounds act as competitive inhibitors of
p53–MDM2 interaction that bind to MDM2. Thus it seems that
the role of MDM2 in promoting motility may also be amenable
to similar drug targeting once the key target protein/s involved
in this mechanism of action is/are discovered.
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